Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202

Pharmacogenetics and Genomics

Volumn 24, Issue 4, 2014, Pages 195-203

  Johnson, Daniel H ^a   Venuto, Charles ^b   Ritchie, Marylyn D ^d   Morse, Gene D ^c   Daar, Eric S ^e   McLaren, Paul J ^f,g   Haas, David W ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

^f EPFL   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

atazanavir; HIV; pharmacogenomics; pharmacokinetics; UGT1A1

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLUCURONOSYLTRANSFERASE 1A1; HEMOGLOBIN; PLACEBO; RITONAVIR; GLUCURONOSYLTRANSFERASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; OLIGOPEPTIDE; PYRIDINE DERIVATIVE; UGT1A1 ENZYME;

ADULT; ALLELE; ARTICLE; BILIRUBIN BLOOD LEVEL; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERBILIRUBINEMIA; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETICS; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ACQUIRED IMMUNODEFICIENCY SYNDROME; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BILIRUBIN; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GLUCURONOSYLTRANSFERASE; HIV PROTEASE INHIBITORS; HUMANS; HYPERBILIRUBINEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGOPEPTIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PYRIDINES; RITONAVIR;

EID: 84896394236     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000034     Document Type: Article

References (51)

1. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
2. Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007; 44:1484-1492.
3. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-456.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: Department of Health and Human Services. Available at: http://aidsinfo.nih. gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. [Accessed 15 August 2013].
5. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33:1729-1739.
6. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008; 47:161-167.
7. Cleijsen RM, van de Ende ME, Kroon FP, Lunel FV, Koopmans PP, Gras L, et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother 2007; 60:897-900.
8. Torti C, Lapadula G, Antinori A, Quirino T, Maserati R, Castelnuovo F, et al. Hyperbilirubinemia during atazanavir treatment in 2, 404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. Infection 2009; 37:244-249.
9. Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Belloso WH, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis 2010; 51:855-864.
10. McDonald C, Uy J, Hu W, Wirtz V, Juethner S, Butcher D, et al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS 2012; 26:259-264.
11. Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis 2011; 52:1267-1275.
12. Bristol-Myers Squibb. Reyataz Package Insert. Princeton, NJ: Bristol-Myers Squibb; 2012.
13. Janneh O, Jones E, Chandler B, Owen A, Khoo SH. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2007; 60:987-993.
14. Rodriguez-Novoa S, Barreiro P, Rendon A, Barrios A, Corral A, Jimenez-Nacher I, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006; 42:291-295.
15. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, Gonzalez-Pardo G, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007; 21:41-46.
16. Kile DA, MaWhinney S, Aquilante CL, Rower JE, Castillo-Mancilla JR, Anderson PL. A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses 2012; 28:1227-1234.
17. Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, et al. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother 2009; 64:1071-1079.
18. Wempe MF, Anderson PL. Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment. Drug Metab Dispos 2011; 39:522-527.
19. Siccardi M, D'Avolio A, Baietto L, Gibbons S, Sciandra M, Colucci D, et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 2008; 47:1222-1225.
20. Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr 2011; 56:412-419.
21. Taburet AM, Piketty C, Chazallon C, Vincent I, Gerard L, Calvez V, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:2091-2096.
22. Dailly E, Tribut O, Tattevin P, Arvieux C, Perre P, Raffi F, Jolliet P. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmaco-kinetics in HIV-infected patients. Eur J Clin Pharmacol 2006; 62:523-526.
23. Acosta EP, Kendall MA, Gerber JG, Alston-Smith B, Koletar SL, Zolopa AR, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Ag Chemother 2007; 51:3104-3110.
24. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005; 44:1035-1050.
25. Colombo S, Buclin T, Cavassini M, Decosterd LA, Telenti A, Biollaz J, Csajka C. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50:3801-3808.
26. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP- glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333:1171-1175.
27. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347:578-581.
28. Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005; 192:1381-1386.
29. Ribaudo HJ, Daar ES, Tierney C, Morse GD, Mollan K, Sax PE, et al. Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis 2013; 207: 420-425.
30. Lubomirov R, Colombo S, di Iulio J, Ledergerber B, Martinez R, Cavassini M, et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis 2011; 203:246-257.
31. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-2240.
32. Haas DW, Wilkinson GR, Kuritzkes DR, Richman DD, Nicotera J, Mahon LF, et al. A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials 2003; 4:287-300.
33. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-1557.
34. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-575.
35. Baudhuin LM, Highsmith WE, Skierka J, Holtegaard L, Moore BE, O'Kane DJ. Comparison of three methods for genotyping the UGT1A1 (TA)n repeat polymorphism. Clin Biochem 2007; 40:710-717.
36. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904-909.
37. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med 2011; 5:795-806.
38. Schipani A, Siccardi M, D'Avolio A, Baietto L, Simiele M, Bonora S, et al. Population pharmacokinetic modeling of the association between 63396C-T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 2010; 54:5242-5250.
39. R: a language and environment for statistical computing. Available at: http://www.R-project.org. [Accessed 15 August 2013].
40. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010; 20:112-120.
41. Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 2010; 20:217-230.
42. Zhang X, Tierney C, Albrecht M, Demeter LM, Morse G, DiFrancesco R, et al. Discordant associations between SLCO1B1 521T-C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. Ther Drug Monit 2013; 35:209-216.
43. Kohlrausch FB, de Cassia Estrela R, Barroso PF, Suarez-Kurtz G. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol 2010; 69:95-98.
44. Rakhmanina NY, Neely MN, Van Schaik RH, Gordish-Dressman HA, Williams KD, Soldin SJ, van den Anker JN. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther Drug Monit 2011; 33:417-424.
45. Chen G, Ramos E, Adeyemo A, Shriner D, Zhou J, Doumatey AP, et al. UGT1A1 is a major locus influencing bilirubin levels in African Americans. Eur J Hum Genet 2012; 20:463-468.
46. Sanna S, Busonero F, Maschio A, McArdle PF, Usala G, Dei M, et al. Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet 2009; 18:2711-2718.
47. Johnson AD, Kavousi M, Smith AV, Chen MH, Dehghan A, Aspelund T, et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet 2009; 18:2700-2710.
48. Castillo-Mancilla JAC, Campbell T, Haas DW, Smeaton L, Wempe MF, Firnhaber C, et al. Effect of CYP3A5 polymorphisms on the metabolism of atazanavir in HIV-infected patients: a sub-study of AIDS Clinical Trials Groups A5175 (NWCS 342). Presented at 13th International Workshop on Clinical Pharmacology of HIV Therapy (Barcelona), 2012. Abstract number 22.
49. Nelson MR, Bacanu SA, Mosteller M, Li L, Bowman CE, Roses AD, et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J 2009; 9:23-33.
50. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008; 359:789-799.
51. Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin Infect Dis 2011; 53:341-348.